Edition:
India

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

4.36USD
19 Jan 2018
Change (% chg)

$0.09 (+2.11%)
Prev Close
$4.27
Open
$4.28
Day's High
$4.41
Day's Low
$4.28
Volume
127,317
Avg. Vol
177,231
52-wk High
$7.66
52-wk Low
$4.08

Select another date:

Mon, Jan 8 2018

BRIEF-Endologix- On Jan 5, Co Delivered Notice Of Termination To Deerfield Elgx Revolver As Agent Under Credit, Security Agreement Dated As Of April 3, 2017

* ENDOLOGIX- ON JAN 5, CO DELIVERED NOTICE OF TERMINATION TO DEERFIELD ELGX REVOLVER AS AGENT UNDER CREDIT, SECURITY AGREEMENT DATED AS OF APRIL 3, 2017

BRIEF-Endologix Q3 loss per share $0.17

* Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Endologix appoints John Onopchenko as chief operating officer

* Endologix appoints John Onopchenko as chief operating officer Source text for Eikon: Further company coverage:

BRIEF-Endologix says operations not materially affected by Santa Rosa fires‍​

* Comments on impact of the Santa Rosa fires impact on co's facility ‍​

BRIEF-ENDOLOGIX GETS FDA NOD TO BEGIN CONFIRMATORY CLINICAL STUDY ON ITS NELLIX EVAS SYSTEM

* ENDOLOGIX RECEIVES IDE APPROVAL FOR THE EVAS2 CONFIRMATORY CLINICAL STUDY TO EVALUATE THE NELLIX® ENDOVASCULAR ANEURYSM SEALING SYSTEM

BRIEF-Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System

* Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use

BRIEF-Endologix announces collaboration agreements with Japan Lifeline

* Endologix announces collaboration agreements with Japan Lifeline for the development and commercialization of thoracic endovascular systems in Japan

BRIEF-Endologix Q2 loss per share $0.20

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

Select another date: